Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Pfizer's PF-06425090?
PF-06425090 is a toxoid vaccine commercialized by Pfizer, with a leading Phase III program in Clostridioides difficile Infections (Clostridium difficile...
Data Insights
PF-06425090 by Pfizer for Clostridioides difficile Infections (Clostridium difficile Associated Disease): Likelihood of Approval
PF-06425090 is under clinical development by Pfizer and currently in Phase III for Clostridioides difficile Infections (Clostridium difficile Associated Disease)....